Isamu Okamoto

32.9k total citations · 8 hit papers
383 papers, 13.9k citations indexed

About

Isamu Okamoto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Isamu Okamoto has authored 383 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 302 papers in Pulmonary and Respiratory Medicine, 280 papers in Oncology and 83 papers in Molecular Biology. Recurrent topics in Isamu Okamoto's work include Lung Cancer Treatments and Mutations (275 papers), Lung Cancer Research Studies (128 papers) and Colorectal Cancer Treatments and Studies (89 papers). Isamu Okamoto is often cited by papers focused on Lung Cancer Treatments and Mutations (275 papers), Lung Cancer Research Studies (128 papers) and Colorectal Cancer Treatments and Studies (89 papers). Isamu Okamoto collaborates with scholars based in Japan, United States and South Korea. Isamu Okamoto's co-authors include Kazuhiko Nakagawa, Masahiro Fukuoka, Kazuto Nishio, Nobuyuki Yamamoto, Masayuki Takeda, Yoichi Nakanishi, Takashi Seto, Kazuko Sakai, Eiji Iwama and Junko Tanizaki and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Isamu Okamoto

373 papers receiving 13.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Isamu Okamoto et al. Journal of Clinical Oncology profile →
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 561 citations Makoto Nishio, Kazuhiko Nakagawa et al. profile →
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

2014 525 citations Koichi Azuma, Keiichi Ota et al. profile →
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

2018 511 citations Kazuhiko Nakagawa, Ki Hyeong Lee et al. Journal of Clinical Oncology profile →
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

2020 409 citations Isamu Okamoto et al. Journal of Thoracic Oncology profile →
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →
Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

2013 351 citations Shinya Ueda, Isamu Okamoto et al. Journal of Clinical Oncology profile →
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

2023 95 citations Isamu Okamoto, James Chih‐Hsin Yang et al. profile →

Peers

Countries citing papers authored by Isamu Okamoto

Since Specialization

Citations

This map shows the geographic impact of Isamu Okamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isamu Okamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isamu Okamoto more than expected).

Fields of papers citing papers by Isamu Okamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isamu Okamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isamu Okamoto. The network helps show where Isamu Okamoto may publish in the future.

Co-authorship network of co-authors of Isamu Okamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Isamu Okamoto. A scholar is included among the top collaborators of Isamu Okamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isamu Okamoto. Isamu Okamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy	Cancer Research	Masaki Magari, Youki Ueda et al.	2
2	Association Between Single Nucleotide Polymorphisms and Disease Susceptibility, Survival, and Acute Exacerbation in Idiopathic Pulmonary Fibrosis	Respirology	Kazuya Tsubouchi, Toyoshi Yanagihara et al.	0
3	AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts	Cancer Science	Yosuke Seto, Ken Uchibori et al.	1
4	MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC	Journal of Thoracic Oncology	Ying Cheng, David R. Spigel et al.	1
5	Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.	Journal of Clinical Oncology	James Chih‐Hsin Yang, Jong Seok Lee et al.	50
6	Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases	Frontiers in Immunology	Toyoshi Yanagihara, Kunihiro Suzuki et al.	24
7	MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma	Cancer Science	Yasuto Yoneshima, Koji Okamura et al.	4
8	Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors	Lung Cancer	Hiroyuki Inoue, Yoshimasa Shiraishi et al.	8
9	Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer breakdown →	Clinical Cancer Research	Keiichi Ota, Koichi Azuma et al.	366
10	Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer	Clinical Cancer Research	Takeshi Yoshida, Guolin Zhang et al.	89
11	Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer	Clinical Cancer Research	Junko Tanizaki, Isamu Okamoto et al.	126
12	Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification	Molecular Cancer Therapeutics	Wataru Okamoto, Isamu Okamoto et al.	73
13	Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin	Molecular Cancer Therapeutics	Kunio Okamoto, Isamu Okamoto et al.	59
14	Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer	Clinical Cancer Research	Ken Takezawa, Isamu Okamoto et al.	115
15	Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors	Molecular Cancer Therapeutics	Isamu Okamoto, Hiroyasu Kaneda et al.	79
16	Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor	Molecular Cancer Therapeutics	Ken Takezawa, Isamu Okamoto et al.	63
17	FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth	Cancer Research	Hiroyasu Kaneda, Tokuzo Arao et al.	157
18	Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition	Molecular Cancer Therapeutics	Wataru Okamoto, Isamu Okamoto et al.	58
19	Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations	Cancer Research	Kunio Okamoto, Isamu Okamoto et al.	75
20	Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells	Clinical Cancer Research	Tsutomu Iwasa, Isamu Okamoto et al.	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact